PharmaShots | Incisive News in 3 Shots

Subscribe Now

adalimumab

STADA and Alvotech Launch AVT02 (biosimilar, adalimumab) for the Treatment of Inflammatory Conditions

STADA and Alvotech Launch AVT02 (biosimilar, adalimumab) for the Treatment of Inflammatory Conditions

June 9, 2022

Pfizer Reports Results of PF-06410293 (biosimilar, adalimumab) in the Sub-Study for the Treatment of Rheumatoid Arthritis

Pfizer Reports Results of PF-06410293 (biosimilar, adalimumab) in the Sub-Study for the Treatment of Rheumatoid Arthritis

April 16, 2022

Celltrion Launches Yuflyma (biosimilar, adalimumab) for the Treatment of Multiple Chronic Inflammatory Disease in Canada

Celltrion Launches Yuflyma (biosimilar, adalimumab) for the Treatment of Multiple Chronic Inflammatory Disease in Canada

April 11, 2022

Alvotech Resolved European Patent Dispute with AbbVie for AVT02 (biosimilar, adalimumab)

Alvotech Resolved European Patent Dispute with AbbVie for AVT02 (biosimilar, adalimumab)

April 6, 2022

Alvotech Entered into a Settlement Agreement with AbbVie for AVT02 (biosimilar, adalimumab)

Alvotech Entered into a Settlement Agreement with AbbVie for AVT02 (biosimilar, adalimumab)

March 8, 2022

Junshi & Mabwell Bioscience’s Junmaikang (biosimilar, adalimumab) Receive the NMPA’s Approval for the Treatment of RA & Two Other Indication

Junshi & Mabwell Bioscience’s Junmaikang (biosimilar, adalimumab) Receive the NMPA’s Approval for the Treatment of RA & Two Other...

March 8, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us